{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:25:29Z","timestamp":1788305129293,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"DOI":"10.7759\/cureus.95632","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T04:47:47Z","timestamp":1761713267000},"source":"Crossref","is-referenced-by-count":5,"title":["Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review"],"prefix":"10.7759","author":[{"given":"George S","family":"Zacharia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudharsan R","family":"Gongati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayush","family":"Kharel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101898","article-title":"Global burden and future trends of metabolic dysfunction-associated steatotic liver disease: 1990-2021 to 2045","volume":"30","author":"Kan C","year":"2025","unstructured":"Kan C, Zhang K, Wang Y, et al.. Global burden and future trends of metabolic dysfunction-associated steatotic liver disease: 1990-2021 to 2045. Ann Hepatol. 2025, 30:101898. 10.1016\/j.aohep.2025.101898","journal-title":"Ann Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam SJ","year":"2024","unstructured":"Keam SJ. Resmetirom: first approval. Drugs. 2024, 84:729-35. 10.1007\/s40265-024-02045-0","journal-title":"Drugs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.r1788","article-title":"Semaglutide: FDA approves weight loss jab to treat severe liver disease","volume":"390","author":"Bowie K","year":"2025","unstructured":"Bowie K. Semaglutide: FDA approves weight loss jab to treat severe liver disease. BMJ. 2025, 390:r1788. 10.1136\/bmj.r1788","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas","volume":"79","author":"Mojsov S","year":"1987","unstructured":"Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987, 79:616-9. 10.1172\/JCI112855","journal-title":"J Clin Invest"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(87)81430-8","article-title":"Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut","volume":"211","author":"Holst JJ","year":"1987","unstructured":"Holst JJ, Orskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 1987, 211:169-74. 10.1016\/0014-5793(87)81430-8","journal-title":"FEBS Lett"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man","volume":"2","author":"Kreymann B","year":"1987","unstructured":"Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987, 2:1300-4. 10.1016\/s0140-6736(87)91194-9","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/651757","article-title":"Multiple factors related to the secretion of glucagon-like peptide-1","volume":"2015","author":"Wang X","year":"2015","unstructured":"Wang X, Liu H, Chen J, Li Y, Qu S. Multiple factors related to the secretion of glucagon-like peptide-1. Int J Endocrinol. 2015, 2015:651757. 10.1155\/2015\/651757","journal-title":"Int J Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7753(14)70101-0","article-title":"The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus (Article in Spanish)","volume":"143 Suppl 2","author":"Escalada FJ","year":"2014","unstructured":"Escalada FJ. The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus (Article in Spanish). Med Clin (Barc). 2014, 143 Suppl 2:2-7. 10.1016\/S0025-7753(14)70101-0","journal-title":"Med Clin (Barc)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.15.2.270","article-title":"Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects","volume":"15","author":"Nathan DM","year":"1992","unstructured":"Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF. Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care. 1992, 15:270-6. 10.2337\/diacare.15.2.270","journal-title":"Diabetes Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199205143262003","article-title":"Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus","volume":"326","author":"Gutniak M","year":"1992","unstructured":"Gutniak M, Orskov C, Holst JJ, Ahr\u00e9n B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992, 326:1316-22. 10.1056\/NEJM199205143262003","journal-title":"N Engl J Med"},{"key":"ref11","article-title":"Exenatide","author":"Bridges A","year":"2025","unstructured":"Bridges A, Bistas KG, Jacobs TF. Exenatide. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2415550121","article-title":"The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity","volume":"121","author":"Friedman JM","year":"2024","unstructured":"Friedman JM. The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity. Proc Natl Acad Sci U S A. 2024, 121:e2415550121. 10.1073\/pnas.2415550121","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer X","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al.. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015, 373:11-22. 10.1056\/NEJMoa1411892","journal-title":"N Engl J Med"},{"key":"ref14","article-title":"Glucagon-Like Peptide-1 Receptor Agonists","author":"Collins L","year":"2025","unstructured":"Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1398059","article-title":"Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity","volume":"11","author":"Tamayo-Trujillo R","year":"2024","unstructured":"Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S, et al.. Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Front Nutr. 2024, 11:1398059. 10.3389\/fnut.2024.1398059","journal-title":"Front Nutr"},{"key":"ref16","article-title":"Semaglutide","author":"Kommu S","year":"2025","unstructured":"Kommu S, Whitfield P. Semaglutide. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial","volume":"42","author":"Zinman B","year":"2019","unstructured":"Zinman B, Aroda VR, Buse JB, et al.. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019, 42:2262-71. 10.2337\/dc19-0898","journal-title":"Diabetes Care"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies M","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, et al.. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021, 397:971-84. 10.1016\/S0140-6736(21)00213-0","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome PN","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al.. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021, 384:1113-24. 10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.13037","article-title":"Semaglutide improves metabolic dysfunction-associated steatohepatitis: a 10-year retrospective study","volume":"8","author":"Shah P","year":"2024","unstructured":"Shah P, White M, Sievert A, et al.. Semaglutide improves metabolic dysfunction-associated steatohepatitis: a 10-year retrospective study. JGH Open. 2024, 8:e13037. 10.1002\/jgh3.13037","journal-title":"JGH Open"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba R","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, et al.. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023, 8:511-22. 10.1016\/S2468-1253(23)00068-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal AJ","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al.. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025, 392:2089-99. 10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ph18071075","article-title":"Semaglutide in MASLD patients: improved survival and liver outcomes","volume":"18","author":"Suki M","year":"2025","unstructured":"Suki M, Amer J, Milgrom Y, et al.. Semaglutide in MASLD patients: improved survival and liver outcomes. Pharmaceuticals (Basel). 2025, 18:1075. 10.3390\/ph18071075","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16651","article-title":"Semaglutide and MASH resolution: a pooled analysis of recent trials","volume":"27","author":"Abouelmagd AA","year":"2025","unstructured":"Abouelmagd AA, Elazab A, Gabra MD, Abosheaishaa H. Semaglutide and MASH resolution: a pooled analysis of recent trials. Diabetes Obes Metab. 2025, 27:6072-7. 10.1111\/dom.16651","journal-title":"Diabetes Obes Metab"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10752-9","article-title":"Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study","volume":"19","author":"Kuo CC","year":"2025","unstructured":"Kuo CC, Chuang MH, Li CH, Huang PY, Kuo HT, Lai CC. Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study. Hepatol Int. 2025, 19:395-404. 10.1007\/s12072-024-10752-9","journal-title":"Hepatol Int"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15898","article-title":"Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: a prospective, multicentre, observational study","volume":"26","author":"Arai T","year":"2024","unstructured":"Arai T, Atsukawa M, Tsubota A, et al.. Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: a prospective, multicentre, observational study. Diabetes Obes Metab. 2024, 26:4958-65. 10.1111\/dom.15898","journal-title":"Diabetes Obes Metab"},{"key":"ref28","unstructured":"FDA approves treatment for serious liver disease known as \u2018MASH\u2019. (2025). Accessed. 29 September, 2025: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng Z","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024, 9:234. 10.1038\/s41392-024-01931-z","journal-title":"Signal Transduct Target Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.17037","article-title":"Mechanism of semaglutide in MASLD treatment: where is the master key?","volume":"40","author":"Ezhilarasan D","year":"2025","unstructured":"Ezhilarasan D. Mechanism of semaglutide in MASLD treatment: where is the master key?. J Gastroenterol Hepatol. 2025, 40:2163-75. 10.1111\/jgh.17037","journal-title":"J Gastroenterol Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206100","article-title":"Semaglutide treatment effects on liver fat content in obese subjects with metabolic-associated steatotic liver disease (MASLD)","volume":"13","author":"Dusilov\u00e1 T","year":"2024","unstructured":"Dusilov\u00e1 T, Kov\u00e1\u0159 J, La\u0148kov\u00e1 I, et al.. Semaglutide treatment effects on liver fat content in obese subjects with metabolic-associated steatotic liver disease (MASLD). J Clin Med. 2024, 13:6100. 10.3390\/jcm13206100","journal-title":"J Clin Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-024-05507-6","article-title":"GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells","volume":"81","author":"da Silva Lima N","year":"2024","unstructured":"da Silva Lima N, Cabaleiro A, Novoa E, et al.. GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells. Cell Mol Life Sci. 2024, 81:468. 10.1007\/s00018-024-05507-6","journal-title":"Cell Mol Life Sci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1046130","article-title":"Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model","volume":"13","author":"Niu S","year":"2022","unstructured":"Niu S, Chen S, Chen X, et al.. Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model. Front Endocrinol (Lausanne). 2022, 13:1046130. 10.3389\/fendo.2022.1046130","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108494","article-title":"Semaglutide has beneficial effects on non-alcoholic steatohepatitis in LDLR-\/-.Leiden mice","volume":"24","author":"Inia JA","year":"2023","unstructured":"Inia JA, Stokman G, Morrison MC, et al.. Semaglutide has beneficial effects on non-alcoholic steatohepatitis in LDLR-\/-.Leiden mice. Int J Mol Sci. 2023, 24:8494. 10.3390\/ijms24108494","journal-title":"Int J Mol Sci"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01025-x","article-title":"Clinical pharmacokinetics of oral semaglutide: analyses of data from clinical pharmacology trials","volume":"60","author":"Overgaard RV","year":"2021","unstructured":"Overgaard RV, Navarria A, Ingwersen SH, B\u00e6kdal TA, Kildemoes RJ. Clinical pharmacokinetics of oral semaglutide: analyses of data from clinical pharmacology trials. Clin Pharmacokinet. 2021, 60:1335-48. 10.1007\/s40262-021-01025-x","journal-title":"Clin Pharmacokinet"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.07.008","article-title":"The use of semaglutide in patients with renal failure-a retrospective cohort study","volume":"30","author":"Long JJ","year":"2024","unstructured":"Long JJ, Sahi SS, Lemke AI, et al.. The use of semaglutide in patients with renal failure-a retrospective cohort study. Endocr Pract. 2024, 30:963-9. 10.1016\/j.eprac.2024.07.008","journal-title":"Endocr Pract"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2024.08.024","article-title":"Glucagon-like peptide-1 receptor agonist use in pregnancy: a review","volume":"232","author":"Drummond RF","year":"2025","unstructured":"Drummond RF, Seif KE, Reece EA. Glucagon-like peptide-1 receptor agonist use in pregnancy: a review. Am J Obstet Gynecol. 2025, 232:17-25. 10.1016\/j.ajog.2024.08.024","journal-title":"Am J Obstet Gynecol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S470826","article-title":"Clinical pharmacokinetics of semaglutide: a systematic review","volume":"18","author":"Yang XD","year":"2024","unstructured":"Yang XD, Yang YY. Clinical pharmacokinetics of semaglutide: a systematic review. Drug Des Devel Ther. 2024, 18:2555-70. 10.2147\/DDDT.S470826","journal-title":"Drug Des Devel Ther"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.03.020","article-title":"Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species","volume":"104","author":"Jensen L","year":"2017","unstructured":"Jensen L, Helleberg H, Roffel A, et al.. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017, 104:31-41. 10.1016\/j.ejps.2017.03.020","journal-title":"Eur J Pharm Sci"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.26502\/aimr.0189","article-title":"Semaglutide: double-edged sword with risks and benefits","volume":"8","author":"Pillarisetti L","year":"2025","unstructured":"Pillarisetti L, Agrawal DK. Semaglutide: double-edged sword with risks and benefits. Arch Intern Med Res. 2025, 8:1-13. 10.26502\/aimr.0189","journal-title":"Arch Intern Med Res"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084346","article-title":"Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (Ozempic) therapy for diabetes mellitus and obesity: a systematic literature review","volume":"25","author":"Feier CV","year":"2024","unstructured":"Feier CV, Vonica RC, Faur AM, Streinu DR, Muntean C. Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (Ozempic) therapy for diabetes mellitus and obesity: a systematic literature review. Int J Mol Sci. 2024, 25:4346. 10.3390\/ijms25084346","journal-title":"Int J Mol Sci"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24315","article-title":"Titration and discontinuation of semaglutide for weight management in commercially insured US adults","volume":"33","author":"Xu Y","year":"2025","unstructured":"Xu Y, Carrero JJ, Chang AR, et al.. Titration and discontinuation of semaglutide for weight management in commercially insured US adults. Obesity (Silver Spring). 2025, 33:1243-8. 10.1002\/oby.24315","journal-title":"Obesity (Silver Spring)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.r205","article-title":"GLP-1 agonists may raise risk of pulmonary aspiration during surgery, MHRA warns","volume":"388","author":"Mahase E","year":"2025","unstructured":"Mahase E. GLP-1 agonists may raise risk of pulmonary aspiration during surgery, MHRA warns. BMJ. 2025, 388:r205. 10.1136\/bmj.r205","journal-title":"BMJ"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.0081","article-title":"Postoperative aspiration pneumonia among adults using GLP-1 receptor agonists","volume":"8","author":"Chen YH","year":"2025","unstructured":"Chen YH, Zink T, Chen YW, et al.. Postoperative aspiration pneumonia among adults using GLP-1 receptor agonists. JAMA Netw Open. 2025, 8:e250081. 10.1001\/jamanetworkopen.2025.0081","journal-title":"JAMA Netw Open"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01008","article-title":"New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs","volume":"104","author":"Gether IM","year":"2019","unstructured":"Gether IM, Nex\u00f8e-Larsen C, Knop FK. New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs. J Clin Endocrinol Metab. 2019, 104:2463-72. 10.1210\/jc.2018-01008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12833","article-title":"Use of incretin agents and risk of acute and chronic pancreatitis: a population-based cohort study","volume":"19","author":"Knapen LM","year":"2017","unstructured":"Knapen LM, de Jong RG, Driessen JH, et al.. Use of incretin agents and risk of acute and chronic pancreatitis: a population-based cohort study. Diabetes Obes Metab. 2017, 19:401-11. 10.1111\/dom.12833","journal-title":"Diabetes Obes Metab"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.04.007","article-title":"Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis","volume":"133","author":"Marzioni M","year":"2007","unstructured":"Marzioni M, Alpini G, Saccomanno S, et al.. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology. 2007, 133:244-55. 10.1053\/j.gastro.2007.04.007","journal-title":"Gastroenterology"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.05.011","article-title":"A case report of allergy to exenatide","volume":"2","author":"P\u00e9rez E","year":"2014","unstructured":"P\u00e9rez E, Mart\u00ednez-Tadeo J, Callero A, Hern\u00e1ndez G, Rodr\u00edguez-Plata E, Garc\u00eda-Robaina JC. A case report of allergy to exenatide. J Allergy Clin Immunol Pract. 2014, 2:822-3. 10.1016\/j.jaip.2014.05.011","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen L","year":"2010","unstructured":"Bjerre Knudsen L, Madsen LW, Andersen S, et al.. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010, 151:1473-86. 10.1210\/en.2009-1272","journal-title":"Endocrinology"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.113","article-title":"Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas","volume":"28","author":"Waser B","year":"2015","unstructured":"Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC. Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Mod Pathol. 2015, 28:391-402. 10.1038\/modpathol.2014.113","journal-title":"Mod Pathol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.786732","article-title":"Corrigendum: safety of semaglutide","volume":"12","author":"Smits MM","year":"2021","unstructured":"Smits MM, Van Raalte DH. Corrigendum: safety of semaglutide. Front Endocrinol (Lausanne). 2021, 12:786732. 10.3389\/fendo.2021.786732","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref52","unstructured":"Ozempen.com. MARCS-CMS 684435. (2024). Accessed: 29 September, 2025: https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/warning-letters\/ozempencom-684435-...."},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3390\/jdb13030029","article-title":"GLP-1-mediated pregnancy and neonatal complications in mice","volume":"13","author":"Ramamoorthy R","year":"2025","unstructured":"Ramamoorthy R, Carden AK, Hussain H, et al.. GLP-1-mediated pregnancy and neonatal complications in mice. J Dev Biol. 2025, 13:29. 10.3390\/jdb13030029","journal-title":"J Dev Biol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1177\/1753495X251346330","article-title":"Pregnancy outcomes following first trimester exposure to semaglutide","author":"Morton A","year":"2025","unstructured":"Morton A, He J. Pregnancy outcomes following first trimester exposure to semaglutide. Obstet Med. 2025, 1753495X251346330. 10.1177\/1753495X251346330","journal-title":"Obstet Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.15092","article-title":"Semaglutide and pregnancy","volume":"163","author":"Skov K","year":"2023","unstructured":"Skov K, Mandic IN, Nyborg KM. Semaglutide and pregnancy. Int J Gynaecol Obstet. 2023, 163:699-700. 10.1002\/ijgo.15092","journal-title":"Int J Gynaecol Obstet"},{"key":"ref56","unstructured":"Highlights of prescribing information. WEGOVY (semaglutide) injection. (2025). Accessed: 17 October, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215256s024lbl.pdf."},{"key":"ref57","unstructured":"FSRH statement. glucagon-like peptide-1 (GLP-1) agonists and oral contraception. (2025). Accessed: 17 October, 2025: https:\/\/www.cosrh.org\/Common\/Uploaded%20files\/documents\/CEU-statement-GLP-1-agonists-and-contraception.pdf."},{"key":"ref58","unstructured":"Clinical guidance. drug interactions with hormonal contraception. (2022). Accessed: 17 October, 2025: https:\/\/www.cosrh.org\/Common\/Uploaded%20files\/documents\/drug-interactions-with-hormonal-contraception-5may2022.pdf."},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3390\/nu16172886","article-title":"Subcutaneous semaglutide during breastfeeding: infant safety regarding drug transfer into human milk","volume":"16","author":"Diab H","year":"2024","unstructured":"Diab H, Fuquay T, Datta P, Bickel U, Thompson J, Krutsch K. Subcutaneous semaglutide during breastfeeding: infant safety regarding drug transfer into human milk. Nutrients. 2024, 16:2886. 10.3390\/nu16172886","journal-title":"Nutrients"},{"key":"ref60","article-title":"Drugs and Lactation Database (LactMed\u00ae)","author":"National Institute of Child Health and Human Development","year":"2024","unstructured":"National Institute of Child Health and Human Development. Drugs and Lactation Database (LactMed\u00ae). National Institute of Child Health and Human Development, Bethesda, MD; 2024."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/425491-semaglutide-in-metabolic-dysfunction-associated-steatohepatitis-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T04:47:58Z","timestamp":1761713278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/425491-semaglutide-in-metabolic-dysfunction-associated-steatohepatitis-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":60,"URL":"https:\/\/doi.org\/10.7759\/cureus.95632","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,28]]}}}